Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 268
Filter
Add more filters

Complementary Medicines
Publication year range
1.
J Clin Endocrinol Metab ; 107(1): 230-240, 2022 01 01.
Article in English | MEDLINE | ID: mdl-34473295

ABSTRACT

CONTEXT: Vitamin D regulates glucose homeostasis pathways, but effects of vitamin D supplementation on ß-cell function remain unclear. OBJECTIVE: To investigate the effects of vitamin D3 supplementation on insulin sensitivity and ß-cell function. METHODS: This is a prespecified secondary analysis of the Vitamin D and Type 2 Diabetes study. Overweight/obese adults at high risk for type 2 diabetes (prediabetes) were randomly treated with vitamin D3 4000 IU or matching placebo daily for 24 months. MAIN OUTCOME: Disposition index (DI), as an estimate of ß-cell function, was calculated as the product of Homeostasis Model Assessment 2 indices derived from C-peptide values (HOMA2%Scpep) and C-peptide response during the first 30 minutes of a 75-g oral glucose tolerance test (OGTT). RESULTS: Mean age was 60.5 ± 9.8 years and body mass index was 31.9 ± 4.4 kg/m2. Mean serum 25(OH)D level increased from 27.9 ± 10.3 ng/mL at baseline to 54.9 ng/mL at 2 years in the vitamin D group and was unchanged (28.5 ± 10.0 ng/mL) in the placebo group. The baseline DI predicted incident diabetes independent of the intervention. In the entire cohort, there were no significant differences in changes in DI, HOMA2%Scpep, or C-peptide response between the 2 groups. Among participants with baseline 25(OH)D level <12 ng/mL, the mean percent differences for DI between the vitamin D and placebo groups was 8.5 (95% CI, 0.2-16.8). CONCLUSIONS: Supplementation with vitamin D3 for 24 months did not improve an OGTT-derived index of ß-cell function in people with prediabetes not selected based on baseline vitamin D status; however, there was benefit among those with very low baseline vitamin D status.


Subject(s)
Cholecalciferol/administration & dosage , Diabetes Mellitus, Type 2/epidemiology , Insulin-Secreting Cells/metabolism , Prediabetic State/diet therapy , Vitamin D Deficiency/diet therapy , Aged , Blood Glucose/metabolism , Diabetes Mellitus, Type 2/diagnosis , Diabetes Mellitus, Type 2/metabolism , Diabetes Mellitus, Type 2/prevention & control , Dietary Supplements , Female , Follow-Up Studies , Glucose Tolerance Test , Humans , Incidence , Insulin/metabolism , Insulin Resistance , Male , Middle Aged , Overweight/blood , Overweight/complications , Overweight/diet therapy , Overweight/metabolism , Prediabetic State/blood , Prediabetic State/diagnosis , Prediabetic State/metabolism , Treatment Outcome , Vitamin D/analogs & derivatives , Vitamin D/blood , Vitamin D Deficiency/blood , Vitamin D Deficiency/diagnosis , Vitamin D Deficiency/metabolism
2.
J Clin Endocrinol Metab ; 107(1): 98-108, 2022 01 01.
Article in English | MEDLINE | ID: mdl-34508607

ABSTRACT

CONTEXT: Vitamin D has been linked with glucose and lipid metabolism. Men with impaired gonadal function have a higher risk of metabolic syndrome and mortality, and vitamin D status may be a reversible modulator. OBJECTIVE: This work aimed to determine the effect of daily vitamin D and calcium supplementation for 150 days on glucose and lipid homeostasis in infertile men. METHODS: A single-center, double-blinded, randomized clinical trial (NCT01304927) was conducted. A total of 307 infertile men were randomly assigned (1:1) to a single dose of 300 000 IU cholecalciferol followed by 1400 IU cholecalciferol + 500 mg of calcium daily (n = 151) or placebo (n = 156) for 150 days. Reported metabolic parameters including fasting plasma glucose, glycated hemoglobin A1c, fasting serum insulin, homeostatic model assessment of insulin resistance (HOMA-IR), fasting plasma cholesterols, and triglycerides were secondary end points. The primary end point semen quality has previously been reported. RESULTS: Men receiving vitamin D supplementation improved their vitamin D status, whereas vitamin D status was aggravated in the placebo group characterized by higher serum parathyroid hormone. At the end of the trial, men receiving vitamin D supplementation had 13% lower fasting serum insulin concentrations compared with the placebo-treated group (65 vs 74 pmol/L, P = .018) and 19% lower HOMA-IR (2.2 vs 2.7, P = .025). Moreover, men in the vitamin D group had higher high-density lipoprotein (HDL) cholesterol levels (1.38 vs 1.32 mmol/L, P = .008) compared with the placebo group. CONCLUSION: High-dose vitamin D supplementation has beneficial effects on glucose homeostasis and HDL cholesterol levels in infertile men.


Subject(s)
Cholecalciferol/administration & dosage , Dietary Supplements , Infertility, Male/diet therapy , Insulin/blood , Vitamin D Deficiency/diet therapy , Adult , Blood Glucose/analysis , Blood Glucose/metabolism , Calcium/administration & dosage , Cholesterol, HDL/blood , Cholesterol, HDL/metabolism , Fasting/blood , Fasting/metabolism , Glycated Hemoglobin/analysis , Glycated Hemoglobin/metabolism , Humans , Infertility, Male/blood , Infertility, Male/diagnosis , Infertility, Male/metabolism , Insulin/metabolism , Insulin Resistance , Male , Semen Analysis , Treatment Outcome , Triglycerides/blood , Triglycerides/metabolism , Vitamin D/analogs & derivatives , Vitamin D/blood , Vitamin D Deficiency/blood , Vitamin D Deficiency/diagnosis , Vitamin D Deficiency/metabolism
3.
Molecules ; 26(17)2021 Aug 31.
Article in English | MEDLINE | ID: mdl-34500722

ABSTRACT

Vitamin D is essential in assuring bone health at all stages of life, but its non-skeletal effects are also essential: This vitamin impacts the physiology of the immune system, skeletal muscles and adipose tissue, glucose metabolism, skin, cardiovascular and reproductive systems, neuro-cognitive functions and cell division. The incidence of vitamin D deficiency is widespread worldwide, at any age, in young and healthy subjects, as well as in pregnant women and the elderly population, due to several factors, including inadequate sunlight exposure, skin pigmentation and coverage, adiposity, lifestyle and low dietary intakes. To overcome this problem, the fortification of foods that are consumed on a daily basis, such as milk, is strongly advisable. This opinion paper aims to discuss, in a multidisciplinary way, the current evidence supporting the importance of vitamin D in health and disease and the role of milk as an optimal carrier of this vitamin, to promote adequate intakes, highlighting its unique physico-chemical characteristics linked to both fat globule membrane and casein micelle structure. Moreover, it addresses the impact of industrial processing and storage of consumption milk on the stability of these structures, thus in determining vitamin D bioavailability and the achievement of adequate intakes.


Subject(s)
Milk , Vitamin D Deficiency/diet therapy , Vitamin D/analysis , Animals , Bone and Bones , Cattle , Dietary Supplements , Food, Fortified
4.
Mol Cell Biochem ; 476(12): 4351-4362, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34453644

ABSTRACT

Vitamin D is an immunomodulatory hormone with an established role in calcium and phosphate metabolism and skeletal mineralization. Evidence showing its immunological benefits by regulating essential components of the innate and adaptive immune system is prevalent. Vitamin D deficiency is reported worldwide and is thereby found to be associated with various immune-related diseases. Rheumatoid Arthritis and COVID-19 are two such diseases, sharing a similar hyperinflammatory response. Various studies have found an association of lower Vitamin D levels to be associated with both these diseases. However, contrasting data is also reported. We review here the available scientific data on risk factor association and supplementation benefits of Vitamin D in Rheumatoid Arthritis and COVID-19, intending to critically evaluate the literature.


Subject(s)
Arthritis, Rheumatoid/diet therapy , COVID-19/etiology , Vitamin D Deficiency/complications , Vitamin D/physiology , Arthritis, Rheumatoid/etiology , Humans , Risk Factors , Vitamin D/immunology , Vitamin D/therapeutic use , Vitamin D Deficiency/diet therapy
5.
J Fam Pract ; 70(6): 289-292, 2021 07.
Article in English | MEDLINE | ID: mdl-34431774

ABSTRACT

USPSTF findings would support screening selective populations at risk for deficiency. But the value of supplements for prevention is nil or still unknown.


Subject(s)
Diet Therapy/standards , Dietary Supplements/standards , Family Practice/standards , Mass Screening/standards , Vitamin D Deficiency/diet therapy , Vitamin D Deficiency/diagnosis , Vitamin D/therapeutic use , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Middle Aged , Practice Guidelines as Topic , Risk Assessment , United States
6.
Nutrients ; 13(7)2021 Jul 17.
Article in English | MEDLINE | ID: mdl-34371953

ABSTRACT

Background Vitamin D deficiency occurs in as much as 90-95% of the Polish population, although this condition is known to cause negative long-term health implications. The role of medical doctors in advising proper supplementation, monitoring and correcting the levels of 25-hydroxyvitamin D in individuals is of great importance and should be used to help mitigate its common deficits. The aim of this study was to evaluate knowledge, attitudes and practices of Polish physicians regarding vitamin D supplementation in order to identify areas for improvement and determinants for the knowledge gaps. Methods The study group comprised 701 medical doctors aged 32.1 ± 5.3 years on average, mostly women (71.61%). An original survey questionnaire was developed for the purpose of the study. Results The mean vitamin D knowledge score was 6.8 ± 2.3 (in a scale 0-13) and was related to gender (p < 0.001), type of specialization (p = 0.032), D3 supplements use (p < 0.001), recommending supplementation to patients (p = 0.005), to relatives and friends (p < 0.001) and to healthy adults (p < 0.001). In terms of self-administration, 14% of respondents take vitamin D all-year-round while 24% only in autumn and winter. 25% of respondents monitor their vitamin D (25-hydroxyvitamin D) serum concentration. Most participants (61%) did not recommend supplementing vitamin D to their patients on a regular basis. Conclusions The study indicates that medical doctors in Poland need to have more training and education on vitamin D supplementation in order to better address the problem of its deficits in the population.


Subject(s)
Dietary Supplements , Health Knowledge, Attitudes, Practice , Physicians , Vitamin D Deficiency , Vitamin D , Vitamins , Adult , Female , Humans , Male , Middle Aged , Poland , Vitamin D/administration & dosage , Vitamin D/analogs & derivatives , Vitamin D/blood , Vitamin D Deficiency/diet therapy , Vitamin D Deficiency/epidemiology , Vitamin D Deficiency/prevention & control , Vitamins/administration & dosage
7.
J Pediatr Endocrinol Metab ; 34(12): 1515-1523, 2021 Dec 20.
Article in English | MEDLINE | ID: mdl-34416104

ABSTRACT

OBJECTIVES: Preterm infants are at increased risk for vitamin D deficiency (VDD). We aimed to assess the adequacy of standardized vitamin D supplementation protocol in very low birth weight (VLBW) infants. Additionally, vitamin D status of mother/infant couples and the associations between vitamin D status at birth and morbidities of the infants were investigated. METHODS: In this single-center, prospective cohort study blood samples were collected from 55 mothers just before delivery and from their infants at birth and on the 30th day of life (DOL) for 25 hydroxy vitamin D (25OHD) measurements. Vitamin D was initiated in dose of 160 IU/kg by parenteral nutrition on the first DOL and oral vitamin D supplementation (400 IU/day) was administered when enteral feedings reached 50% of total intake or on the 15th DOL. RESULTS: The median 25OHD levels of the infants were 16.12 (9.14-20.50) in cord blood and 36.32 (31.10-44.44) in venous blood on the 30th DOL (p<0.01). In 98% of the VLBW infants 25OHD reached sufficient levels on the 30th DOL. None of the mothers had sufficient vitamin D levels (25OHD >30 ng/mL). Maternal 25OHD levels were correlated with the 25OHD levels of the infants in cord blood (r=0.665, p<0.001). There was a significant difference in mean cord 25OHD levels between winter (13.65 ± 5.69 ng/mL) and summer seasons (19.58 ± 11.67 ng/mL) (p=0.021). No association was found between neonatal morbidity and vitamin D status. CONCLUSIONS: The results clearly show that by utilizing the current supplementation protocol, the majority of VLBW infants with deficient/insufficient serum 25OHD levels reached sufficient levels on the 30th DOL. Furthermore, vitamin D levels in mother/infant couples were found to be highly correlated.


Subject(s)
Dietary Supplements/standards , Infant, Premature/growth & development , Infant, Very Low Birth Weight/growth & development , Vitamin D Deficiency/diet therapy , Vitamin D/analogs & derivatives , Adult , Female , Follow-Up Studies , Humans , Infant, Newborn , Male , Prognosis , Prospective Studies , Vitamin D/administration & dosage , Vitamin D/standards , Young Adult
8.
J Steroid Biochem Mol Biol ; 213: 105964, 2021 10.
Article in English | MEDLINE | ID: mdl-34390830

ABSTRACT

OBJECTIVE: We aimed to evaluate the vitamin D status of pregnant women with COVID-19, and the association between vitamin D level and severity of COVID-19. METHODS: In this case control study, 159 women with a single pregnancy and tested positive for SARS-CoV-2, and randomly selected 332 healthy pregnant women with similar gestational ages were included. COVID-19 patients were classified as mild, moderate, and severe. Vitamin D deficiency was defined as 25-hydroxycholecalciferol <20 ng/mL (50 nmol/L), and 25-OH D vitamin <10 ng/mL was defined as severe vitamin D deficiency, also 25-OH D vitamin level between 20-29 ng/mL (525-725 nmol/L) was defined as vitamin D insufficiency. RESULTS: Vitamin D levels of the pregnant women in the COVID-19 group (12.46) were lower than the control group (18.76). 25-OH D vitamin levels of those in the mild COVID-19 category (13.69) were significantly higher than those in the moderate/severe category (9.06). In terms of taking vitamin D supplementation, there was no statistically significant difference between the groups. However, it was observed that all of those who had severe COVID-19 were the patients who did not take vitamin D supplementation. CONCLUSION: The vitamin D levels are low in pregnant women with COVID-19. Also, there is a significant difference regarding to vitamin D level and COVID-19 severity in pregnant women. Maintenance of adequate vitamin D level can be useful as an approach for the prevention of an aggressive course of the inflammation induced by this novel coronavirus in pregnant women.


Subject(s)
COVID-19/diet therapy , Cytokine Release Syndrome/diet therapy , Dietary Supplements , Pregnancy Complications, Infectious/diet therapy , Vitamin D Deficiency/diet therapy , Vitamin D/administration & dosage , Adult , COVID-19/blood , COVID-19/pathology , COVID-19/virology , Calcifediol/blood , Case-Control Studies , Cytokine Release Syndrome/blood , Cytokine Release Syndrome/pathology , Cytokine Release Syndrome/virology , Female , Gestational Age , Humans , Pregnancy , Pregnancy Complications, Infectious/blood , Pregnancy Complications, Infectious/pathology , Pregnancy Complications, Infectious/virology , SARS-CoV-2/pathogenicity , Severity of Illness Index , Treatment Outcome , Vitamin D/analogs & derivatives , Vitamin D/blood , Vitamin D Deficiency/blood , Vitamin D Deficiency/pathology , Vitamin D Deficiency/virology
9.
J Steroid Biochem Mol Biol ; 213: 105958, 2021 10.
Article in English | MEDLINE | ID: mdl-34332023

ABSTRACT

BACKGROUND: The objective of this extension phase of the quasi-experimental GERIA-COVID study was to determine whether vitamin D3 supplementation taken prior to or during COVID-19 was associated with better 3-month survival in geriatric patients hospitalized for COVID-19. METHODS: Intervention group was defined as all participants supplemented with vitamin D3 prior to or during COVID-19 (n = 67). Supplements were either bolus vitamin D3 (ie, 50,000 IU per month, or 80,000 IU or 100,000 IU or 200,000 IU every 2-3 months), or daily supplementation with 800 IU. Comparator group involved those without vitamin D supplements (n = 28). Outcome was 3-month mortality. Covariables were age, sex, functional abilities, history of malignancies, cardiomyopathy, undernutrition, number of acute health issues, antibiotics use, systemic corticosteroids use, and 25(OH)D concentration. RESULTS: 76.1 % (n = 51) of participants survived at 3 months in Intervention group, compared to only 53.6 % (n = 15) in Comparator group (P = 0.03). The fully-adjusted hazard ratio for 3-month mortality was HR = 0.23 [95 %CI: 0.09;0.58](P = 0.002) in Intervention group compared to Comparator group. Intervention group had also longer survival time (log-rank P = 0.008). CONCLUSIONS: Vitamin D3 supplementation was associated with better 3-month survival in older COVID-19 patients.


Subject(s)
COVID-19/diet therapy , Cardiomyopathies/diet therapy , Cholecalciferol/administration & dosage , Dietary Supplements , Malnutrition/diet therapy , Neoplasms/diet therapy , Vitamin D Deficiency/diet therapy , Vitamin D/analogs & derivatives , Aged, 80 and over , COVID-19/blood , COVID-19/mortality , COVID-19/virology , Cardiomyopathies/blood , Cardiomyopathies/mortality , Cardiomyopathies/virology , Case-Control Studies , Comorbidity , Drug Administration Schedule , Female , Health Services for the Aged , Humans , Male , Malnutrition/blood , Malnutrition/mortality , Malnutrition/virology , Neoplasms/blood , Neoplasms/mortality , Neoplasms/virology , Proportional Hazards Models , SARS-CoV-2/pathogenicity , Vitamin D/blood , Vitamin D Deficiency/blood , Vitamin D Deficiency/mortality , Vitamin D Deficiency/virology
10.
Eur J Endocrinol ; 185(2): 333-342, 2021 Jul 07.
Article in English | MEDLINE | ID: mdl-34128826

ABSTRACT

OBJECTIVE: GC/DBP effects on response to vitamin D supplementation have not been well-studied. Thus we assessed free and total 25-OHD after vitamin D treatment across the six common GC haplotypes. DESIGN: This double-blind, randomized study compared two vitamin D3 doses in healthy, urban-dwelling 6-month to 10-year-old children at-risk for vitamin D deficiency. Randomization was stratified by GC haplotype. METHODS: Children were randomized to receive 2800 or 7000 International Units of vitamin D3 weekly. 25-OHD and 1,25(OH)2D were sampled at baseline and after 1-6 months of supplementation. RESULTS AND CONCLUSIONS: One hundred ninety-two of 225 enrolled subjects completed the study. After one month, total 25-OHD increased with both doses and were higher with 7000 IU/week (85.5 ± 22.8 nmol/L) compared to 2800 IU/week (76.8 ± 18.0 nmol/L), despite equivalent baseline levels. No further significant increase occurred at 6 months (89.8 ± 35.5 and 74.3 ± 18.3 nmol/L, respectively). Free 25-OHD similarly changed. 25-OHD differed among GC groups at baseline. Although no significant effects of individual GC haplotypes on incremental changes were evident, a trend toward an effect of combined 'at risk' GC alleles on response was evident (P = 0.06). Total 1,25(OH)2D showed modest increases, moreso with the larger dose. In urban-dwelling children at-risk for vitamin D deficiency, 1 month of vitamin D3 2800 IU/week increased 25-OHD across all GC haplotype groups, and somewhat enhanced with 7000 IU/week with no further significant increases after 6 months of supplementation. Free 25-OHD measures offer no monitoring advantage over total 25-OHD.


Subject(s)
25-Hydroxyvitamin D 2/blood , Cholecalciferol/administration & dosage , Cholecalciferol/blood , Haplotypes/physiology , Vitamin D Deficiency/blood , Vitamin D Deficiency/diet therapy , Child , Child, Preschool , Dietary Supplements , Double-Blind Method , Female , Humans , Infant , Male , Prospective Studies , Vitamin D Deficiency/diagnosis
11.
Int J Mol Sci ; 22(9)2021 May 10.
Article in English | MEDLINE | ID: mdl-34068701

ABSTRACT

In addition to its canonical functions, vitamin D has been proposed to be an important mediator of the immune system. Despite ample sunshine, vitamin D deficiency is prevalent (>80%) in the Middle East, resulting in a high rate of supplementation. However, the underlying molecular mechanisms of the specific regimen prescribed and the potential factors affecting an individual's response to vitamin D supplementation are not well characterized. Our objective is to describe the changes in the blood transcriptome and explore the potential mechanisms associated with vitamin D3 supplementation in one hundred vitamin D-deficient women who were given a weekly oral dose (50,000 IU) of vitamin D3 for three months. A high-throughput targeted PCR, composed of 264 genes representing the important blood transcriptomic fingerprints of health and disease states, was performed on pre and post-supplementation blood samples to profile the molecular response to vitamin D3. We identified 54 differentially expressed genes that were strongly modulated by vitamin D3 supplementation. Network analyses showed significant changes in the immune-related pathways such as TLR4/CD14 and IFN receptors, and catabolic processes related to NF-kB, which were subsequently confirmed by gene ontology enrichment analyses. We proposed a model for vitamin D3 response based on the expression changes of molecules involved in the receptor-mediated intra-cellular signaling pathways and the ensuing predicted effects on cytokine production. Overall, vitamin D3 has a strong effect on the immune system, G-coupled protein receptor signaling, and the ubiquitin system. We highlighted the major molecular changes and biological processes induced by vitamin D3, which will help to further investigate the effectiveness of vitamin D3 supplementation among individuals in the Middle East as well as other regions.


Subject(s)
Cholecalciferol/genetics , Immunomodulation/immunology , Lipopolysaccharide Receptors/genetics , Toll-Like Receptor 4/genetics , Vitamin D/genetics , Adolescent , Adult , Cholecalciferol/administration & dosage , Cholecalciferol/immunology , Dietary Supplements , Female , Gene Expression/drug effects , Humans , Immunomodulation/drug effects , Nutrition Therapy , Vitamin D/immunology , Vitamin D Deficiency/diet therapy , Vitamin D Deficiency/genetics , Vitamin D Deficiency/immunology , Vitamin D Deficiency/pathology , Young Adult
12.
Clin Transl Sci ; 14(6): 2111-2116, 2021 11.
Article in English | MEDLINE | ID: mdl-34057814

ABSTRACT

This review describes the evidence for the potential benefit of vitamin D supplementation in people with respiratory diseases who may have a higher susceptibility to coronavirus disease 2019 (COVID-19) infection and its consequences. Clinical evidence indicates that vitamin D may reduce the risk of both upper and lower respiratory tract infections and offers benefit particularly in people with vitamin D deficiency. Some evidence exists for a higher incidence of active tuberculosis (TB) in patients who are deficient in vitamin D. An association between low levels of 25(OH)D (the active form of vitamin D) and COVID-19 severity of illness and mortality has also been reported. In addition, low 25(OH)D levels are associated with poor outcomes in acute respiratory distress syndrome (ARDS). The cytokine storm experienced in severe COVID-19 infections results from excessive release of pro-inflammatory cytokines. Due to its immunomodulatory effects, adequate vitamin D levels may cause a decrease in the pro-inflammatory cytokines and an increase in the anti-inflammatory cytokines during COVID-19 infections. Vitamin D deficiency was found in 82.2% of hospitalized COVID-19 cases and 47.2% of population-based controls (p < 0.0001). The available evidence warrants an evaluation of vitamin D supplementation in susceptible populations with respiratory diseases, such as TB, and particularly in those who are deficient in vitamin D. This may mitigate against serious complications of COVID-19 infections or reduce the impact of ARDS in those who have been infected.


Subject(s)
COVID-19/immunology , Dietary Supplements , Tuberculosis/immunology , Vitamin D Deficiency/diet therapy , Vitamin D/administration & dosage , COVID-19/diagnosis , COVID-19/epidemiology , COVID-19/prevention & control , Comorbidity , Cytokine Release Syndrome/immunology , Cytokine Release Syndrome/prevention & control , Cytokine Release Syndrome/virology , Disease Susceptibility/blood , Disease Susceptibility/immunology , Humans , Pandemics , Respiratory Distress Syndrome/immunology , Respiratory Distress Syndrome/prevention & control , Risk Factors , Severity of Illness Index , Tuberculosis/blood , Tuberculosis/epidemiology , Vitamin D/blood , Vitamin D Deficiency/complications , Vitamin D Deficiency/epidemiology , Vitamin D Deficiency/immunology
13.
Nutrients ; 13(4)2021 Apr 14.
Article in English | MEDLINE | ID: mdl-33919716

ABSTRACT

BACKGROUND AND AIMS: Vitamin D is synthesized in the skin with the aid of ultraviolet-B radiation, playing a variety of roles in the body. Temporomandibular disorders (TMDs) are a group of pathological conditions involving the temporomandibular joints as well as the masticatory muscles and othersurrounding tissues. In the present narrative review, we investigated the potential role of vitamin D in the etiology of temporomandibular disorders in order todetermine whether the current knowledge supports 25-hidroxyvitamin D (25-OHD) supplementation in temporomandibular disorders associated with insufficient or deficient levels of vitamin D. METHODS: A literature research was performed in PubMed, Scopus, Science Direct, and Google Scholar databases, and a total of 10 articles were included for analysis. RESULTS: Among the observational studies published to date, investigating the role for vitamin D in the etiology of TMDs, six of them suggest that there is a connection between the two aspects. In this context, patients suffering from TMD, with deficient levels of vitamin D (<30 ng/mL), are most likely to benefit from supplementation, whereas individuals with vitamin D level >50ng/mL probably have little benefit from supplementation. CONCLUSION: Vitamin D might be a safe, simple, and potentially beneficial way to prevent TMDs or to reduce pain; however, more randomized and placebo-controlled trials are required before any firm conclusions can be drawn.


Subject(s)
Dietary Supplements , Masticatory Muscles/physiopathology , Temporomandibular Joint Disorders/diet therapy , Vitamin D Deficiency/diet therapy , Vitamin D/analogs & derivatives , Humans , Observational Studies as Topic , Temporomandibular Joint Disorders/blood , Temporomandibular Joint Disorders/etiology , Temporomandibular Joint Disorders/physiopathology , Treatment Outcome , Vitamin D/administration & dosage , Vitamin D/blood , Vitamin D Deficiency/blood , Vitamin D Deficiency/complications , Vitamin D Deficiency/diagnosis
14.
Expert Rev Respir Med ; 15(6): 805-821, 2021 06.
Article in English | MEDLINE | ID: mdl-33858268

ABSTRACT

Introduction: Viral respiratory tract infections (RTIs) have been recognized as a global public health burden. Despite current theories about their effectiveness, the true benefits of dietary supplements on the prevention and treatment of viral RTIs remain elusive, due to contradictory reports. Hence, we aimed to evaluate the effectiveness of dietary supplements on the prevention and treatment of viral RTIs.Areas covered: We systematically searched databases of PubMed, Web of Science, Scopus, and Google Scholar through 4 March 2020, to identify randomized controlled trials that evaluated the effects of consuming selected dietary supplements on the prevention or treatment of viral RTIs.Expert opinion: Thirty-nine randomized controlled trials (n = 16,797 participants) were eligible and included. Namely, vitamin D supplementation appeared to improve viral RTIs across cohorts particulate in those with vitamin D deficiency. Among the evaluated dietary supplements, specific lactobacillus strains were used most commonly with selected prebiotics that showed potentially positive effects on the prevention and treatment of viral RTIs. Further, ginseng extract supplementation may effectively prevent viral RTIs as adjuvant therapy. However, longitudinal research is required to confirm these observations and address the optimal dose, duration, and safety of dietary supplements being publicly recommended.


Subject(s)
COVID-19/prevention & control , COVID-19/therapy , Dietary Supplements , Respiratory Tract Infections , Virus Diseases , COVID-19/complications , COVID-19/epidemiology , Dietary Supplements/classification , Drugs, Chinese Herbal/therapeutic use , Humans , Lactobacillus/physiology , Panax/chemistry , Quercetin/therapeutic use , Randomized Controlled Trials as Topic/statistics & numerical data , Respiratory Tract Infections/epidemiology , Respiratory Tract Infections/prevention & control , Respiratory Tract Infections/therapy , SARS-CoV-2/physiology , Virus Diseases/epidemiology , Virus Diseases/prevention & control , Virus Diseases/therapy , Vitamin D/therapeutic use , Vitamin D Deficiency/complications , Vitamin D Deficiency/diet therapy , Vitamin D Deficiency/epidemiology , beta-Glucans/therapeutic use
15.
Front Endocrinol (Lausanne) ; 12: 583654, 2021.
Article in English | MEDLINE | ID: mdl-33889131

ABSTRACT

Calcium and vitamin D are inseparable nutrients required for bone health. In the past half a century, the dietary calcium intake of rural, tribal, and urban India has declined. Though India is the largest producer of milk and cereals, the major source of calcium in India is through non-dairy products. The highest intake of cereals and lowest intake of milk & milk products was observed in rural and tribal subjects whereas, the intake of cereals, milk & milk products were similar in both urban and metropolitan subjects. One of the reasons for lower calcium intake was the proportion of calcium derived from dairy sources. Over the past half a century, the average 30-day consumption of cereals in the rural and urban population has declined by 30%. The Per Capita Cereal Consumption (PCCC)has declined despite sustained raise in Monthly Per capita Consumption Expenditure (MPCE) in both rural and urban households. The cereal consumption was the highest in the lowest income group, despite spending smaller portion of their income, as cereals were supplied through public distribution system (PDS). About 85% of the Indian population are vitamin D deficient despite abundant sunlight. Dietary calcium deficiency can cause secondary vitamin D deficiency. Though India as a nation is the largest producer of milk, there is profound shortage of calcium intake in the diet with all negative consequences on bone health. There is a decline in dietary calcium in the background of upward revision of RDI/RDA. There is a gap in the production-consumption-supply chain with respect to dietary calcium. To achieve a strong bone health across India, it is imperative to have population based strategies addressing different segments including supplementing dietary/supplemental calcium in ICDS, mid-day-meals scheme, public distribution system, educational strategies. Other measures like mass food fortification, biofortification, bioaddition, leveraging digital technologies, investments from corporate sector are some measures which can address this problem. India is a vast country with diverse social, cultural and dietary habits. No single measure can address this problem and requires a multi-pronged strategic approach to tackle the dietary calcium deficiency to achieve strong bone health while solving the problem of nutritional deficiency.


Subject(s)
Calcium Metabolism Disorders/epidemiology , Calcium/deficiency , Calcium Metabolism Disorders/blood , Calcium Metabolism Disorders/diet therapy , Calcium, Dietary/administration & dosage , Female , Food, Fortified/statistics & numerical data , Food, Fortified/supply & distribution , History, 20th Century , History, 21st Century , Humans , India/epidemiology , Male , Nutritional Status/physiology , Recommended Dietary Allowances , Retrospective Studies , Vitamin D/administration & dosage , Vitamin D/blood , Vitamin D Deficiency/blood , Vitamin D Deficiency/diet therapy , Vitamin D Deficiency/epidemiology
16.
Pediatr Pulmonol ; 56(2): 354-361, 2021 02.
Article in English | MEDLINE | ID: mdl-32930511

ABSTRACT

Excess adipose tissue predisposes to an enhanced inflammatory state and can contribute to the pathogenesis and severity of asthma. Vitamin D has anti-inflammatory properties and low-serum levels are seen in children with asthma and in children with obesity. Here we review the intersection of asthma, obesity, and hypovitaminosis D in children. Supplementation with vitamin D has been proposed as a simple, safe, and inexpensive adjunctive therapy in a number of disease states. However, little research has examined the pharmacokinetics of vitamin D and its therapeutic potential in children who suffer from obesity-related asthma.


Subject(s)
Asthma , Dietary Supplements , Obesity , Vitamin D , Vitamins , Asthma/blood , Asthma/diet therapy , Asthma/etiology , Child , Humans , Inflammation/blood , Inflammation/diet therapy , Obesity/blood , Obesity/complications , Obesity/diet therapy , Obesity/metabolism , Vitamin D/blood , Vitamin D/pharmacokinetics , Vitamin D/therapeutic use , Vitamin D Deficiency/blood , Vitamin D Deficiency/diet therapy , Vitamins/blood , Vitamins/pharmacokinetics , Vitamins/therapeutic use
17.
J Allergy Clin Immunol ; 147(4): 1234-1241.e3, 2021 04.
Article in English | MEDLINE | ID: mdl-32822692

ABSTRACT

BACKGROUND: Childhood asthma developmental programming is complex. Maternal asthma is a strong risk factor for childhood asthma, whereas vitamin D (VD) has emerged as a modifiable prenatal exposure. OBJECTIVE: Our aim was to examine the combined effect of early and late prenatal VD status in during pregnancies in women with and without asthma on childhood asthma or recurrent wheeze development. METHODS: We conducted a cohort study using prospectively collected data from the Vitamin D Antenatal Asthma Reduction Trial, a randomized, double-blinded, placebo-controlled VD supplementation trial in pregnant women at high risk of offspring asthma (N = 806 mother-offspring pairs). 25-Hydroxyvitamin-D (25(OH)D) level was measured in early and late pregnancy. Our main exposure was an ordered variable representing early and late prenatal VD sufficiency (25(OH)D level ≥ 30 ng/mL) status during pregnancy in women with and without asthma. The primary outcome was offspring with asthma or recurrent wheeze by age 3 years. We also examined the effect of prenatal VD level on early life asthma or recurrent wheeze progression to active asthma at age 6 years. RESULTS: Among mothers with asthma versus among mothers with early and late prenatal VD insufficiency, those with early or late VD sufficiency (adjusted odds ratio = 0.56; 95% CI = 0.31-1.00) or early and late VD sufficiency (adjusted odds ratio = 0.36; 95% CI = 0.15-0.81) had a lower risk of offspring with asthma or recurrent wheeze by age 3 years (Pfor trend = .008). This protective trend was reiterated in asthma or recurrent wheeze progression to active asthma from age 3 to 6 years (Pfor trend = .04). CONCLUSION: This study implies a protective role for VD sufficiency throughout pregnancy, particularly in attenuating the risk conferred by maternal asthma on childhood asthma or recurrent wheeze development.


Subject(s)
Asthma/epidemiology , Prenatal Exposure Delayed Effects/epidemiology , Vitamin D Deficiency/epidemiology , Vitamin D/therapeutic use , Adult , Asthma/diet therapy , Child , Child, Preschool , Cohort Studies , Dietary Supplements , Double-Blind Method , Female , Humans , Male , Maternal Exposure , Placebo Effect , Pregnancy , Pregnancy Trimesters , Prenatal Exposure Delayed Effects/diet therapy , Prospective Studies , Recurrence , Respiratory Sounds , Risk , Vitamin D/metabolism , Vitamin D Deficiency/diet therapy , Young Adult
18.
PLoS One ; 15(12): e0241459, 2020.
Article in English | MEDLINE | ID: mdl-33378408

ABSTRACT

OBJECTIVE: The association between vitamin D deficiency and multiple sclerosis (MS) is well described. We set out to use remote sampling to ascertain vitamin D status and vitamin D supplementation in a cross-sectional study of people with MS across the UK. METHODS: People with MS and matched controls were recruited from across the UK. 1768 people with MS enrolled in the study; remote sampling kits were distributed to a subgroup. Dried blood spots (DBS) were used to assess serum 25(OH)D in people with MS and controls. RESULTS: 1768 MS participants completed the questionnaire; 388 MS participants and 309 controls provided biological samples. Serum 25(OH)D was higher in MS than controls (median 71nmol/L vs 49nmol/L). A higher proportion of MS participants than controls supplemented (72% vs 26%, p<0.001); people with MS supplemented at higher vD doses than controls (median 1600 vs 600 IU/day, p<0.001). People with MS who did not supplement had lower serum 25(OH)D levels than non-supplementing controls (median 38 nmol/L vs 44 nmol/L). Participants engaged well with remote sampling. CONCLUSIONS: The UK MS population have higher serum 25(OH)D than controls, mainly as a result of vitamin D supplementation. Remote sampling is a feasible way of carrying out large studies.


Subject(s)
Dietary Supplements , Multiple Sclerosis/blood , Vitamin D Deficiency/blood , Vitamin D/blood , Adult , Aged , Case-Control Studies , Cross-Sectional Studies , Dried Blood Spot Testing , Female , Humans , Male , Middle Aged , Multiple Sclerosis/complications , Multiple Sclerosis/diagnosis , Multiple Sclerosis/diet therapy , Surveys and Questionnaires , United Kingdom , Vitamin D/administration & dosage , Vitamin D Deficiency/complications , Vitamin D Deficiency/diagnosis , Vitamin D Deficiency/diet therapy
20.
J Transl Med ; 18(1): 322, 2020 08 26.
Article in English | MEDLINE | ID: mdl-32847594

ABSTRACT

The coronavirus disease 2019 (COVID-19) pandemic has led to a declaration of a Public Health Emergency of International Concern by the World Health Organization. As of May 18, 2020, there have been more than 4.7 million cases and over 316,000 deaths worldwide. COVID-19 is caused by a highly infectious novel coronavirus known as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), leading to an acute infectious disease with mild-to-severe clinical symptoms such as flu-like symptoms, fever, headache, dry cough, muscle pain, loss of smell and taste, increased shortness of breath, bilateral viral pneumonia, conjunctivitis, acute respiratory distress syndromes, respiratory failure, cytokine release syndrome (CRS), sepsis, etc. While physicians and scientists have yet to discover a treatment, it is imperative that we urgently address 2 questions: how to prevent infection in immunologically naive individuals and how to treat severe symptoms such as CRS, acute respiratory failure, and the loss of somatosensation. Previous studies from the 1918 influenza pandemic have suggested vitamin D's non-classical role in reducing lethal pneumonia and case fatality rates. Recent clinical trials also reported that vitamin D supplementation can reduce incidence of acute respiratory infection and the severity of respiratory tract diseases in adults and children. According to our literature search, there are no similar findings of clinical trials that have been published as of July 1st, 2020, in relation to the supplementation of vitamin D in the potential prevention and treatment for COVID-19. In this review, we summarize the potential role of vitamin D extra-renal metabolism in the prevention and treatment of the SARS-CoV-2 infection, helping to bring us slightly closer to fulfilling that goal. We will focus on 3 major topics here: 1. Vitamin D might aid in preventing SARS-CoV-2 infection: Vitamin D: Overview of Renal and Extra-renal metabolism and regulation. Vitamin D: Overview of molecular mechanism and multifaceted functions beyond skeletal homeostasis. Vitamin D: Overview of local immunomodulation in human infectious diseases. Anti-viral infection. Anti-malaria and anti-systemic lupus erythematosus (SLE). 2. Vitamin D might act as a strong immunosuppressant inhibiting cytokine release syndrome in COVID-19: Vitamin D: Suppression of key pro-inflammatory pathways including nuclear factor kappa B (NF-kB), interleukin-6 (IL-6), and tumor necrosis factor (TNF). 3. Vitamin D might prevent loss of neural sensation in COVID-19 by stimulating expression of neurotrophins like Nerve Growth Factor (NGF): Vitamin D: Induction of key neurotrophic factors. .


Subject(s)
Chemoprevention/methods , Coronavirus Infections/prevention & control , Coronavirus Infections/therapy , Immunomodulation/drug effects , Neuroprotective Agents/therapeutic use , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Pneumonia, Viral/therapy , Vitamin D/therapeutic use , Betacoronavirus/drug effects , Betacoronavirus/physiology , Brain/drug effects , Brain/physiology , COVID-19 , Coronavirus Infections/epidemiology , Coronavirus Infections/physiopathology , Dietary Supplements , Humans , Immune System/drug effects , Immune System/physiology , Neuroprotection/drug effects , Pneumonia, Viral/epidemiology , Pneumonia, Viral/physiopathology , SARS-CoV-2 , Vitamin D/metabolism , Vitamin D/pharmacology , Vitamin D Deficiency/diet therapy , Vitamin D Deficiency/epidemiology , Vitamin D Deficiency/metabolism , Vitamin D Deficiency/virology
SELECTION OF CITATIONS
SEARCH DETAIL